Navigation Links
Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
Date:8/6/2009

MORRISTOWN, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's pending acquisition of privately held Arrow Group. The information request was issued under notification requirements of the Hart.Scott.Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"). The effect of the second request is to extend the waiting period imposed by the HSR Act until 30 days after Watson and Arrow Group have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC. Watson intends to cooperate fully with the FTC's review and continues to expect the transaction to close in the second half of 2009.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... UK (PRWEB) , ... May 06, 2016 , ... ... success in changing the way the pharmaceutical industry conducts clinical trials. This month Ibs ... most influential people in pharma, and he was honored as a Tech Disruptor by ...
(Date:5/6/2016)... ... ... variety of national pet product manufacturers, companies and brands will gather for one day only ... noon to 8 p.m. at New York City’s Roger Smith Hotel. The event is produced ... and safety pet products in today’s marketplace. , Petrend Event showcases the newest ...
(Date:5/6/2016)... , ... May 06, 2016 , ... Logically, spring weather, ... seasons, when the weather is too cold, dry or hot, water on the eye ... actually absorb moisture from the surrounding air. There’s only one problem, according to radio ...
(Date:5/6/2016)... ... 2016 , ... Canadian author Mark Black is a speaker, author, and life strategy ... the world … with the help of his publisher Strategic Book Group and its subsidiary ... a hospital bed waiting for a miracle: He needed a heart and double-lung transplant. From ...
(Date:5/6/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a new article ... Bible about helping to stop cancer. Yisrayl says there are too many suffering and dying ... and science industries will pay close attention and take action. The Pastor says that the ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... TORONTO , May 5, 2016  Replikins Ltd. today reported initial promising results ... Photo - http://photos.prnewswire.com/prnh/20160505/364345 ... ... ... Replikins analyses of all Zika specimens recorded on Pubmed. The analysis identified the highest ...
(Date:5/5/2016)... 5, 2016  Diagnostic imaging has been on ... concerns that these tests cause health care costs to spike. ... as well as the adoption of new guidelines ... peripherals that help health care providers cut costs, while helping ... imaging is a renowned authorized reseller of the medical ...
(Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
Breaking Medicine Technology: